A recent Italian study of myotonic dystrophy patients concluded that many patients up to 88% may show deficiencies of Vitamin D. Over 40% of patients showed severe Vitamin D deficiencies. Patients with DM may need to consider a multivitamin of Vitamin D supplement to insure adequate nutrition. Many DM patients have less social and ambulatory abilities which may limit their outdoor activities in sunny weather. The sun which is a source of vitamin D.
What is the cost for confirming the diagnosis for Myotonic Dystrophy. Do patents affect this cost? This Data is current as of May 2013
The costs for patents and access to testing is a major cost in the Myotonic Dystrophy Field. Here is a brief review of the costs.
The fast fail initiative is considering many potential autism drugs including Isis Pharmaceutical’s pending drug to treat myotonic dystrophy. This “FAST FAIL” initiative funded by NIH looks at promising drugs to treat Autism and several other conditions. It enables the drug to go to human trials earlier and see if the drug will pan out. The Isis drug by far is the most probable drug to treat and reverse the course of the Autism disease.
I recently became aware of a new and exciting company working on a potential drug therapy in the Myotonic Dystrophy space. Valentia Biopharma S.L. is a biotechnology company born in August 2006 as a University of Valencia spin-off.
Social Widgets powered by AB-WebLog.com.